Marine natural products as anticancer drugs

Molecular Cancer Therapeutics

Volumn 4, Issue 2, 2005, Pages 333-342

  Simmons, T Luke ^a   Andrianasolo, Eric ^a   McPhail, Kerry ^a   Flatt, Patricia ^a   Gerwick, William H ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; APLADIN; AURISTATIN PE; BARBAMIDE; BIPRASIN; CARNITINE; CEMADOTIN; DEHYDRODIDEMNIN B; DIDEMNIN B; DNA METHYLTRANSFERASE; DOCETAXEL; DOLASTATIN 10; DOLASTATIN 15; DYSIDENIN; E 7389; HALICHONDRIN B; HISTONE DEACETYLASE; NATURAL PRODUCT; ORNITHINE DECARBOXYLASE; PLATINUM DERIVATIVE; PSAMMAPLIN A; PSAMMAPLIN F; PSAMMAPLIN G; SOBLIDOTIN; SYNTHADOTIN; TACROLIMUS; TAXANE DERIVATIVE; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID;

ACUTE HEART INFARCTION; ALOPECIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHENIA; ASTROCYTOMA; BLOOD TOXICITY; BREAST CANCER; CARDIOTOXICITY; CLINICAL TRIAL; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG ISOLATION; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLIOBLASTOMA; GYNECOLOGIC CANCER; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FAILURE; LEUKEMIA; LIVER DYSFUNCTION; LIVER FAILURE; LUNG CANCER; MARINE ENVIRONMENT; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MUSCLE ATROPHY; MYELOMA; NAUSEA; NEUROMUSCULAR DISEASE; NEUTROPENIA; NONHUMAN; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RHABDOMYOLYSIS; SHORT SURVEY; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; DEPSIPEPTIDES; DIOXOLES; ETHERS, CYCLIC; HUMANS; ISOQUINOLINES; OCEANS AND SEAS; TETRAHYDROISOQUINOLINES; TYROSINE;

EID: 14844312905     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (78)

1. Venter JC, Remington K, Heidelberg JF, et al. Environmental genome shotgun sequencing of the Sargasso Sea. Science 2004 Apr 2;304:66-74.
2. Williams DH, Stone MJ, Hauck PR, Rahman SK. Why are secondary metabolites (natural products) biosynthesized? J Nat Prod 1989;52: 1189-208.
3. Firn RD, Jones CG. Natural products: a simple model to explain chemical diversity. Nat Prod Rep 2003;20:382-91.
4. Newman DJ, Cragg GM, Kingston DG. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003;66:1022-37.
5. McManus OB, Musick JR, Gonzalez C. Peptides isolated from the venom of Conus geographus block neuromuscular transmission. Neurosci Lett 1987 Aug 7;25:57-62.
6. Saunders PR, Taylor PB. Venom of the lion fish, Pterois volitans. Am J Physiol 1959;197:437-40.
7. Moore RE, Schauer PJ. Palytoxin: new marine toxin from a coelenterate. Science 1971;172:495-8.
8. Hallock YF, Cragg GM. National Cooperative Drug Discovery Groups (NCDDGs): a successful model for public private partnerships in cancer drug discovery. Pharmaceutical Biology 2003;41:78-91.
9. Hildebrand M, Waggoner LE, Lim GE, Sharp KH, Ridley CP, Haygood MG. Approaches to identify, clone, and express symbiont bioactive metabolite genes. Nat Prod Rep 2004;21:122-42.
10. Arabshahi L, Schmitz FJ. Brominated tyrosine metabolites from an unidentified sponge. J Org Chem 1987;52:3584-6.
11. Quiñoà E, Crews P. Phenolic constituents of psammaplysilla. Tet Lett 1987;28:3229-32.
12. Rodriguez AD, Akee R, Schauer P. Two bromotyrosine-cysteine derived metabolites from a sponge. Tetrahedron Lett 1987;28:4989-92.
13. Pina I, Gautschi J, Wang G, et al. Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. J Org Chem 2003;68:3866-73.
14. Kim D, Lee S, Jung J, Lee C, Choi S. Psammaplin A, a natural phenolic compound, has inhibitory effect on human topoisomerase II and is cytotoxic to cancer cells. Anticancer Res 1999;19:4085-90.
15. Shim J, Lee H, Shin J, Kwon H. Psammaplin A, a marine natural product, inhibits aminopeptidase N and suppresses angiogenesis in vitro. Cancer Lett 2004;203:163-9.
16. Remiszewski SW. The discovery of NVP-LAQ824: from concept to clinic. Curr Med Chem 2003;10:2393-402.
17. Developmental Therapeutics Compound Data Base. Bethesda (MD): NIH/National Cancer Institute (US) 2004. Available from: http://dtp.nci.nih.gov/index.html.
18. Rinehart K, Gloer J, Cook J, Carter Jr, Mizsak S, Scahill T. Structures of the didemnins, antiviral and cytotoxic depsipeptides from a Caribbean tunicate. J Am Chem Soc 1987;103:1857-9.
19. Nuijen B, Bouma M, Manada C, et al. Pharmaceutical development of anticancer agents derived from marine sources. Anticancer Drugs 2000;11:793-811.
20. Sings HL, Rinehart KL. Compounds produced from potential tunicate-blue-green algal symbiosis. J Ind Microbiol Biotechnol 1996; 17:385-96.
21. Crampton S, Adams E, Kuentzel S, Li L, Badiner G, Bhuyan B. Biochemical and cellular effects of didemnins A and B. Cancer Res 1984; 23:1796-801.
22. Vera M, Joullie MM. Natural products as probes of cell biology: 20 years of didemnin research. Med Res Rev 2002;22:102-45.
23. Crews CM, Collins JL, Lane WS, Snapper ML, Schreiber SL. GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1 α. J Biol Chem 1994;269:15411-4.
24. Johnson K, Lawen A. Rapamycin inhibits didemnin B-induced apoptosis in human HL-60 cells: evidence for the possible involvement of FK506-binding protein 25. Immunol Cell Biol 1999;77:242-8.
25. Sakai R, Kishore V, Kundu B, et al. Structure-activity relationships of the didemnins. J Med Chem 1996;39:2819-34.
26. Erba E, Serafini M, Gaipa G, et al. Effect of aplidine in acute lymphoblastic leukaemia cells. Br J Cancer 2003;89:763-73.
27. Urdiales J, Morata P, Nunez De Castro I, Sanchez-Jimenez F. Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from mediterranean tunicates. Cancer Lett 1996;102:31-7.
28. Broggini M, Marchini SV, Galliera E, et al. Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia 2004;17:52-9.
29. Jimeno J, Faircloth G, Fernandez Souse-Faro JM, Schauer P, Rinehart K. New marine derived anticancer therapeutics: a journey from the sea to clinical trials. Marine Drugs 2004;2:14-29.
30. Amador ML, Jimeno J, Paz-Ares L, Cortes-Funes H, Hidago M. Progress in the developement and acquisition of anticancer agents from marine sources. Ann Oncol 2003;14:1607-15.
31. Armand JP, Ady-Vago N, Faivre S, et al. Phase I and Pharmacokinetic Study of Aplidine (APL) given as a 24-hour continuous infusion every other week (q2w) in patients (pts) with solid tumor (ST) and lymphoma (NHL). Proceedings of the 2001 American Society of Clinical Oncology Annual Meeting. Abstr #47. In 2001.
32. Harrigan GG, Luesch H, Yoshida WY, et al. Symplostatin 1: a dolastatin 10 analogue from the marine cyanobacterium Symploca hydnoides. J Nat Prod 1998;61:1075-7.
33. Luesch H, Moore RE, Paul VJ, Mooberry SL, Corbett TH, Isolation of dolastatin 10 from the marine cyanobacterium symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1. J Nat Prod 2001;64:907-10.
34. Pettit GR, Kamano Y, Herald CL, et al. The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J Am Chem Soc 1987;109:6883-5.
35. Bai R, Pettit GR, Hamel E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangable nucleotide and Vinca alkaloid sites. J Biol Chem 1990;265:17141-9.
36. Jordan A, Hadfield JA, Lawernce NJ, McGown AT. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 1998;18:259-96.
37. Bai R, Pettit GR, Hamel E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the Vinca alkaloid binding domain. Biochem Pharmacol 1992;43:2637-45.
38. Pitot HC, McElroy EA Jr, Reid JM, et al. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 1999;5:525-31.
39. Vaishampayan U, Glode M, Du W, et al. Phase II Study of Dolastatin 10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clin Cancer Res 2000;6:4205-8.
40. Hoffman M, Blessing J, Lentz S. A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003;89:95-8.
41. Miyazaki K, Kobayashi M, Natsume T, et al. Synthesis and antitumor activity of novel dolastatin 10 analogs. Chem Pharm Bull (Tokyo) 1995;43:1706-18.
42. Kobayashi M, Natsume T, Tamaoki S, et al. Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. Jpn J Cancer Res 1997;88: 316-27.
43. Natsume T, Kobayashi M, Fujimoto S. Association of p53 gene mutations with sensitivity to TZT-1027 in patients with clinical lung and renal carcinoma. Cancer 2001;92:386-94.
44. Natsume T, Watanabe J, Koh Y, et al. Antitumor activity of TZT-1027 (soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo. Cancer Sci 2003;94:826-33.
45. Gerwick WH, Tan LT, Sitachitta N. Nitrogen-containing metabolites from marine cyanobacteria. In: Cordell G, editor. The alkaloids. San Diego: Academic Press; 2001. p. 75-184.
46. Pettit GR, Kamano Y, Dufresne C, Cerny RL, Herald CL, Schmidt JM. Isolation and structure of the cytostatic linear depsipeptide dolastatin 15. J Org Chem 1989;54:6005-6.
47. Cruz-Monserrate Z, Mullaney J, Harran P, Pettit GR, Hamel E. Dolastatin 15 binds in the Vinca domain of tubulin as demonstrated by hummel-dreyer chromatography. Eur J Biochem 2003;270:3822-8.
48. de Arruda M, Cocchiaro CA, Nelson CM, et al. LU103793 (NSC D-669356): a synthetic peptide that interacts with microtubules and inhibits mitosis. Cancer Res 1995;55:3085-92.
49. Villalona-Calero M, Baker S, Hammond LA, et al. Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies. J Clin Oncol 2001;19:857-69.
50. Kerbrat P, Dieras V, Pavlidis N, Ravaud A, Wanders J, Fumoleau P. Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer. Eur J Cancer 2003;39:317-20.
51. Marks R, Graham D, Sloan J, et al. A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer. Am J Clin Oncol 2003;26:336-7.
52. Smyth J, Boneterre ME, Schellens J, et al. Activity of the dolastatin analogue, LU103793, in malignant melanoma. Ann Oncol 2001;12:509-11.
53. Newman DJ, Cragg GM. Marine natural products and related compounds in clinical and advanced preclinical trials. J Nat Prod 2004; 67:1216-38.
54. Ebbinghaus S, Hersh E, Cunningham CC, et al. Phase II study of synthadotin (SYN-D; ILX651) administered daily for 5 consecutive days once every 3 weeks in patients with inoperable locally advanced or metastatic melanoma. Proceedings of the 2004 American Society of Clinical Oncology Annual Meeting; Abstr #7530. In 2004.
55. Rinehart K, Holt T, Fregeau N, et al. Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata. J Org Chem 1990;55:4512-5.
56. Wright A, Forleo D, Gunawardana G, Gunasekera S, Koehn F, McConnell O. Antitumor tetrahydroisoquinoline alkaloids from the colonial ascidian Ecteinascidia turbinata. J Org Chem 1990;55:4508-12.
57. Haygood M, Salomon C, Faulkner JD, inventors; Ecteinascidin family compounds: compositions and methods. International Patent EP1360337. 2003 Nov 12.
58. Perez E, Beatriz A, Perez T, et al, inventors. Sequences from an endosymbiont and their uses. International Patent WO2004015143. 2004 Feb 19.
59. van Kesteren C, de Vooght M, Mathot R, Schellens J, Jimeno JM, Beijnen JH. Yondelis (Trabectedin, ET-743): the development of an anticancer agent of marine origin. Anticancer Drugs 2003;14:487-502.
60. Zewail-Foote M, Hurley L. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 1999;42:2493-7.
61. Dileo P, Casali PG, Bacci G, et al. Phase II evaluation of 3-hr infusion ET-743 in patients with recurrent sarcomas. Proceedings of the 2002 ASCO Annual Meeting. Abstr #1628. In 2002.
62. Krasner CN, McMeekin S, Chan S, et al. A phase II study of weekly trabectedin (ET-743) in second/third line ovarian carcinoma. J Clin Oncol 2004 Jul;22:5045.
63. McMeekin DS, Manikas G, Crispens M, et al. A phase II study of trabectedin (ET-743) as a second line therapy in patients with persistent or recurrent endometrial carcinoma. Proceeding of the 2004 American Society of Clinical Oncology. Abstr #5086. In 2004.
64. Uemura D, Takahashi K, Yamamoto T, et al. Norhalichondrin A: an antitumor polyether macrolide from a marine sponge. J Am Chem Soc 1985;107:4796-8.
65. Bai RL, Paull KD, Herald CL, Malspeis L, Pettit GR, Hamel E. Halichondrin B and homohalichondrin B, marine natural products binding in the Vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 1991; 266:15882-9.
66. Dabydeen D, Florence G, Paterson I, Hamel E. A Quantitative evaluation of the effects of inhibitors of tubulin assembly on polymerization induced by discodermolide, epothilone B, and paclitaxel. Cancer Chemother Pharmacol 2004;53:397-403.
67. Cooper A, Salomon R. Total synthesis of halichondrins: enantioselective construction of a homochiral pentacyclic C1-C15 intermediate from D-ribose. Tetrahedron Lett 1990;31:3813-6.
68. Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001;61:1013-21.
69. Wang Y, Habgood G, Christ W, Littlefield BY, Melvin J. Structure-activity relationships of Halichondrin B analogues: modifications at C.30-C.38. Bioorg Med Chem Lett 2000;10:1029-32.
70. Choi H, Demeke D, Kang F, et al. Synthetic studies on the marine natural product halichondrins. Pure Appl Chem 2003;75:1-17.
71. Kimura T, Synold T, Mahaffey CM, et al. E7389, a novel antimicrotubule agent with potent p53-independent induction of p27, Bcl2 phosphorylation and cytotoxicity in non-small cell lung cancer (NSCLC). Proceedings of the American Society of Clinical Oncology. Abstr. # 2804. In 2003. p. 697.
72. Faulkner DJ, Harper MK, Haygood MG. Symbiotic bacteria in sponges: sources of bioactive substances. In: Fusetani N, editor, Drugs from the sea. Basel, Switz: S. Karger AG; 2000. p. 107-19.
73. Flowers A, Garson MJ, Webb R, Dumdei E, Charan R. Cellular origin of chlorinated diketopiperazines in the dictyoceratid sponge Dysidea herbacea (Keller). Cell Tissue Res 1998;292:597-607.
74. Unson MD, Faulkner DJ. Cyanobacterial symbiont biosynthesis of chlorinated metabolites from Dysidea herbacea (Porifera). Experientia 1993;49:349-53.
75. Orjala JO, Gerwick WH. Barbamide, a chlorinated metabolite with molluscicidal activity from the Caribbean cyanobacterium Lyngbya majuscula. J Nat Prod 1996;59:427-30.
76. Salomon C, Faulkner DJ. Localization studies of bioactive cyclic peptides in the ascidian Lissoclinum patella. J Nat Prod 2002;65:689-92.
77. Schmidt E, Sudek S, Haygood MG. Genetic evidence supports secondary metabolic diversity in prochloron spp., the cyanobacterial symbiont of a tropical ascidian. J Nat Prod 2004;67:1341-5.
78. Salomon CE, Magarvey NA, Sherman DH. Merging the potential of microbial genetics with biological and chemical diversity: an even brighter future for marine natural product drug discovery. Nat Prod Rep 2004;21:105-21.